	US 12,246,074 B2
	Granulocyte colony-stimulating factor (GCSF) gene therapy for treating neurological diseases
Jang-Yen Wu, Boca Raton, FL (US)
Assigned to CHS Pharma Inc., San Francisco, CA (US)
Filed by CHS Pharma Inc., Naples, FL (US)
Filed on Nov. 5, 2020, as Appl. No. 17/089,770.
Application 17/089,770 is a continuation of application No. PCT/US2019/033124, filed on May 20, 2019.
Claims priority of provisional application 62/674,049, filed on May 21, 2018.
Prior Publication US 2021/0052745 A1, Feb. 25, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 48/00 (2006.01); A61P 25/28 (2006.01); C07K 14/535 (2006.01); C12N 15/86 (2006.01)

CPC A61K 48/0066 (2013.01) [A61P 25/28 (2018.01); C07K 14/535 (2013.01); C12N 15/86 (2013.01)]

9 Claims

1. A method of reducing the volume of a brain infarct that develops in a mammalian subject in response to a cerebral ischemia/reperfusion injury caused by ischemic stroke, the method comprising the step of administering to the eye of the subject a viral vector that comprises a recombinant adeno-associated virus comprising a gene encoding human granulocyte colony stimulating factor (GCSF), a neuron-specific promoter operatively linked with the GCSF gene and an hypoxia-sensitive gene switch/biosensor operatively linked with the GCSF gene, wherein the volume of a brain infarct that develops in the mammalian subject as a result of the cerebral ischemia/reperfusion injury is reduced after administration of the viral vector as compared to the volume of a brain infarct in a subject not treated by administration of the viral vector.